Open access
Aug 2026
Eriodictyol regulates LDHB to trigger mitophagy-mediated NLRP3 inflammasome inactivation as a therapeutic strategy for bone loss.
BACKGROUND Imbalance of bone homeostasis triggers abnormal activation of osteoclasts and impaired osteogenic function, which further exacerbates bone resorption, reduces bone mass, and ultimately induces bone loss. Eriodictyol (ERI) possesses a wide range of biological activities and can effectively inhibit excessive b...
Yi-Yuan Wang, Wen Pu, Yuangang Su et al.
· Pharmacological Research · 0 citations